Engelhard Arzneimittel GmbH & Co.KG   Report issue

For profit Phase 2 Phase 3
Founded: Niederdorfelden Germany (1872)
Status: No NME R&D (1872)

Organization Overview

First Clinical Trial
2008
NCT01127048
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (2)

icosapent ethyl (vascepa) (1 trial)

Ivy leaf (1 trial)

Drugs in Phase 2 Trials (1)

ivy leaves (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Attention Deficit Disorder with Hyperactivity (Phase 3)

Bronchitis (Phase 3)

Cough (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 3